Journal Browser

Journal Browser

Special Issue "Poor-Risk and Relapsed/Refractory Germ Cell Tumor"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editor

Prof. Dr. Michal Mego
E-Mail Website
Guest Editor
2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia
Interests: circulating tumor cells; breast cancer; testicular cancer

Special Issue Information

Dear Colleagues,

Germ cell tumors (GCT) belong to the most chemosensitive solid tumors and represent a model for a curable cancer. Cisplatin represents the mainstay in the treatment of GCTs. Cisplatin-based first line chemotherapy can cure about 70–80% of patients with disseminated testicular cancer. Salvage chemotherapy with standard dose cisplatin plus previously not utilized drugs will cure 20–25% of patients who were not initially cured with their induction chemotherapy.

Because of insufficient results in the treatment of poor-risk and relapsed/refractory GCTs, evaluation of new treatment strategies and new drugs with significant antitumor activity, as single-agent or combination treatments, remains a priority. Identification of new biomarkers and/or therapeutic targets remains one of the research goals as well. 

This Special issue of IJMS is focused on advances in research of poor-risk and relapsed/refractory testicular germ cell tumor and articles that cover this topic, including preclinical research, biomarker research, and research that focuses on special subpopulations of patients are welcome.

Prof. Michal Mego
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • testicular germ cell tumors
  • poor-risk
  • multiple relapsed/refractory
  • chemoresistance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Case Report
Recurrence of a Mediastinal Germ-Cell Tumor as a Somatic-Type Malignancy: A Complex Case Report
Int. J. Mol. Sci. 2021, 22(17), 9310; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22179310 - 27 Aug 2021
Viewed by 329
Background and case: An adolescent male presented with a second mediastinal tumor 1.5 years after treatment of a proven malignant germ-cell tumor in that location. The differential diagnosis included a recurrent germ-cell tumor or a non-germ cell malignancy. Serum tumor markers alpha-fetoprotein (AFP) [...] Read more.
Background and case: An adolescent male presented with a second mediastinal tumor 1.5 years after treatment of a proven malignant germ-cell tumor in that location. The differential diagnosis included a recurrent germ-cell tumor or a non-germ cell malignancy. Serum tumor markers alpha-fetoprotein (AFP) and human chorionic gonadotrophin (HCG) were negative. The first biopsy was not informative, and the second biopsy gave a broad differential diagnosis including secondary non-germ cell malignancy using histology and immunohistochemistry. DNA methylation profiling, RNA sequencing, and targeted microRNA371a-3p profiling was subsequently performed, without a supportive result. After resection of the tumor the definitive diagnosis yielded two secondary non-germ cell malignancies in the form of a leiomyosarcoma and a solitary neuro endocrine carcinoma (NEC). In spite of the differences between the molecular profiles of the initial germ-cell tumor, the leiomyosarcoma and large-cell NEC are clonally related, as determined by the presence of identical chromosomal breakpoints. The copy number profiles suggest an initial polyploidization step, followed by various independent chromosomal gains and losses. This case demonstrates that germ-cell tumors must be evaluated carefully, including molecularly, in which the non-germ cell malignancy is negative for miR-371a-3p, both in tissue as well as in serum, in contrast to the primary tumor. We conclude that the patient presented with a primary type II mediastinal GCT and, a year and a half later, followed by a leiomyosarcoma and a large-cell NEC presenting as two secondary somatic-type malignancies clonally related to the original GCT. Conclusions: Malignant germ-cell tumors are known to recur as a somatic-type malignancy in very rare cases. This case report illustrates the challenges faced in defining the nature and clonality of the secondary somatic-type malignancies. Full article
(This article belongs to the Special Issue Poor-Risk and Relapsed/Refractory Germ Cell Tumor)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Planned paper 1:  Growing teratoma syndrome in the setting of post-chemotherapy testicular germ cell tumors

Planned paper 2: High-dose chemotherapy, an unsurpassed frontier of salvage treatment for relapsed germ-cell tumors

Back to TopTop